Movement Alert｜Twist Bioscience Corp Overnight Rise 4.26%, earnings expectations and Eli Lilly collaboration remain in focus

Market Focus11-12 09:55

On November 12, Twist Bioscience Corp rose 4.26% Overnight, trading at $127.81 per share, with turnover of $21,300.

The move coincided with continued market focus on the company’s upcoming quarterly results, consensus expectations for about $123 million in revenue, and progress in its antibody characterization data services collaboration tied to Eli Lilly’s TuneLab platform.

Available market commentary ahead of the November 12 earnings release points to quarterly revenue growth of 25.96% year over year, adjusted EPS expected at a loss of $0.37 to $0.44 per share, and EBIT projected at a loss of about $23.28 million, with narrowing losses and expense efficiency remaining key watchpoints. Separate reports also noted broadly positive institutional sentiment, including an average target price near $150.33, while discussion around AI drug discovery-related orders has added to short-term trading volatility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment